Disclosures for "ICI-Induced Encephalitis Secondary to Pembrolizumab use in Renal Cell Carcinoma: A Case Report"
-
Miss Williams has nothing to disclose.
-
Dr. Malik has nothing to disclose.
-
Dr. Linnoila has received research support from NIH/NINDS. Dr. Linnoila has received personal compensation in the range of $10,000-$49,999 for serving as a expert respondent on autoimmune encephalitis with U.S. government/DHHS/vaccine injury compensation program.
-
Dr. Polonski has nothing to disclose.